{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109718","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.580066+00:00","generated_at":"2026-05-16T21:26:01.602604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter","bullets":["Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.","Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.","Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.","Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.","Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109718","json":"https://secwatch.observer/filing/0001104659-25-109718.json","markdown":"https://secwatch.observer/filing/0001104659-25-109718.md","text":"https://secwatch.observer/filing/0001104659-25-109718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/0001104659-25-109718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:26:01.602604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}